Nation helping meet global demand for medical supplies
As the COVID-19 pandemic hammers a growing number of countries and the world faces a shortage of medical supplies, Chinese drug and medical equipment manufacturers are working round the clock to produce as many products as possible to ensure a stable global medical supply chain.
When the epidemic broke out in China, many medical supply factories, especially those in the hardest-hit Hubei province, were unable to operate given the lockdown by the government to curb the spread of the contagion. As the outbreak in the country has increasingly come under control, plants have resumed operations and sped up their production of critical medical supplies so that surgical masks, protective gowns, ventilators and test kits can be provided not only for China, but also for the rest of the world.
Vice-Foreign Minister Luo Zhaohui said during a recent news conference that China had already offered emergency assistance to 83 countries and regions and international organizations such as the World Health Organization and the African Union. The assistance included test kits, masks and other medical supplies.
Data from the General Administration of Customs showed that from March 1 to April 4, China had inspected and exported epidemic prevention and control supplies worth 10.2 billion yuan ($1.4 billion), including 3.86 billion masks, 37.52 million protective gowns, 2.41 million infrared thermometers, 16,000 ventilators, 2.84 million test kits and 8.41 million pairs of protective goggles.
In face of the crisis, China is taking advantage of its complete industrial system and maximizing its powerful operational capability, Luo said.
At present, dozens of countries, such as the United Kingdom, Germany, Italy, Thailand, South Korea, Japan and Spain, are boosting their imports of masks, ventilators, protective gowns, disinfection materials, monitors, thermometers and test kits from China, industry experts said.
The importing countries were having difficulties in guaranteeing medical supplies. China, as an integral part of the global medical industrial chain, stepped up, they said.
Although affected by the pandemic during its initial stage, as economic activity steadily resumed, production capacity of Chinese factories gradually caught up.
The Ministry of Industry and Information Technology said that as of March 28, the average work resumption rate of the country's industrial enterprises above a designated size of 20 million yuan in revenue each reached 98.6 percent, and the average employee return rate was 89.9 percent.
Even in Hubei, where the outbreak was once the most severe, more than 95 percent of companies had resumed operations, and around 70 percent of employees were back at work.
Compared to large enterprises, work resumption rates at small and medium-sized enterprises reached 76 percent, said the ministry.
"Manufacturing plants for medical supplies and daily necessities had relatively higher return rates," said Xin Guobin, vice-minister of the ministry.
Li Xingqian, director-general of the Ministry of Commerce's Department of Foreign Trade, said China owns the world's largest, most complete and comprehensive manufacturing system, and the advantages of the system are irreplaceable. China's foreign trade development has sufficient resilience, ample room for development and strong innovation capability.
"This long-term positive trend will not change, neither will China's position in the global industrial chain," Li added.
Ever since the novel coronavirus outbreak, the Chinese government has never levied any restrictions on the export of surgical masks, and producers are expected to carry out their business in a principled way according to market forces.
Despite the ongoing battle with the outbreak in China, the Ministry of Commerce said China has not and never will restrict the export of medical supplies, and it will continue to provide supplies to the best of its ability, to help other nations fight the pandemic.
Cao Xuejun, deputy director-general of the MIIT's Consumer Products Industry Department, said currently, the epidemic situation in China has been steadily improving, and the production capacity of masks, protective gowns and other medical supplies increased rapidly, thus greatly alleviating supply shortages.
"We encourage domestic manufacturing enterprises of medical supplies to actively meet foreign demand, standardize production and export according to corresponding standards in contributing to the global fight against the contagion," Cao said.
Starting from April 1, exporters of medical products, including COVID-19 testing kits, masks and ventilators, need to provide extra documentation when they go through customs clearance, said the commerce ministry.
The Chinese government will ramp up efforts from various departments to accelerate the process of exporting crucial medical supplies to the world while strictly controlling product quality, said Zhang Qi, deputy director-general of the Department of Medical Device Regulation under the National Medical Products Administration.
Looking for chemical products? Let suppliers reach out to you!
2026-06-05
-
Life Science Ingredients Industry Overview
This issue offers a deep exploration of the evolving pharmaceutical and nutrition landscape, combining data, analysis, and insight to reveal key industry shifts and emerging directions. Support online permanent download.Published in: Nov. 2025
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Global Countries Impose Tariffs on Chinese Chemical Products
-
China Suspends Sulfuric Acid Exports, Global Copper and Fertilizer Supply Under Strain
-
U.S. Issues Final Anti-Dumping Ruling on Chinese MDI: Dumping Margins Reduced from Over 500% to 85%+
-
DKSH Expands Partnership with Assessa to Distribute Botanical Ingredients Across China
-
A Comprehensive Overview of China’s Special Engineering Materials Market: How Should the Industry Rebuild Its Capabilities Amid Growing Downstream Pressure?
-
India Extends Anti-Dumping Duties on Aniline Imports from China for Five More Years
-
China's Zero Tariff Policy for African Products Brings Opportunities to the Cosmetics and Personal Care Products Industry
-
The United States Lifts Restrictions on Ethane Exports to China, and Trade Relations Show Signs of Easing
-
Iraq and China Cooperate to Launch Large Petrochemical Plant and Green Industrial City
-
South Korean Company Unid Builds New Potassium Hydroxide Plant in Yichang
Recommend Reading
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
India Hosts 22 Nations to Advance Global Drug Standards and Access to Medicines
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Chinese Hydrofluoric Acid Market Shows a Steady and Slightly Strong Trend
-
December Cyclohexane Market Operates Weakly, Lacking Momentum for Price Increases
-
28 Chinese Companies Face FDA Automatic Detention in May 2025
-
August 27 Caustic Soda Prices Firmly Rising in China
-
Cyclohexane Explained: Properties, Uses & Differences from Cyclohexene